Clinical Trials Logo

HRD clinical trials

View clinical trials related to HRD.

Filter by:
  • None
  • Page 1

NCT ID: NCT05069818 Not yet recruiting - Ovarian Cancer Clinical Trials

Variance of HRD From Paired Ovarian Cancer

HOPEII
Start date: October 2021
Phase:
Study type: Observational

Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.

NCT ID: NCT05044091 Not yet recruiting - Ovarian Cancer Clinical Trials

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

HOPEI
Start date: September 15, 2021
Phase:
Study type: Observational

Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer. However, the proportion of HRD positive in real world and relationship of HRD status with PARPi in Chinese ovarian cancer patients remains unknown.

NCT ID: NCT04895046 Withdrawn - Metastatic Cancer Clinical Trials

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Start date: October 11, 2021
Phase: Phase 2
Study type: Interventional

Phase II, single arm trial, evaluating molecularly selected, immune-based combination therapy in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the homologous recombination deficient (HRD) signature.

NCT ID: NCT03415659 Recruiting - Clinical trials for Advanced Solid Tumors

Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

Start date: March 5, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation/dose-expansion, phase I clinical trial study to investigate the safety, tolerability, and efficacy of HWH340. In addition, the pharmacokinetic characteristics will also be investigated. Three parts are included in this study.